MYOPARR

From LncRNAWiki
Revision as of 08:43, 24 July 2019 by Qianpeng Li (talk | contribs) (Created page with "''MYOPARR'', a long noncoding RNA, is essential for the expression of human myogenin gene, which is one of the key myogenic transcription factors. ==Annotated Information== =...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search

MYOPARR, a long noncoding RNA, is essential for the expression of human myogenin gene, which is one of the key myogenic transcription factors.

Annotated Information

Name

Approved symbol: MYOPARR

Approved name: MYOPARR: myogenin promoter-associated myogenic regulatory antisense long non-coding RNA.

HGNC ID: HGNC: 54178

RefSeq ID: NR_160550


Characteristics

MYOPARR


Function

  • MYOPARR is essential both for the specification of myoblasts by activating neighboring myogenin expression and for myoblast cell cycle withdrawal by activating myogenic microRNA expression. Mechanistically, MYOPARR interacts with Ddx17, a transcriptional coactivator of MyoD, and regulates the association between Ddx17 and the histone acetyltransferase PCAF[1].
  • MYOPARR also promotes skeletal muscle atrophy caused by denervation, and knockdown of MYOPARR rescues muscle wasting in mice[1].

Regulation

Diseases

Expression

MYOPARR is coexpressed with myogenin, the expression of which is highly restricted to myogenic tissues in embryonic, fetal, and adult skeletal muscles [1].

Evolution

Labs working on this lncRNA

  • Division for Therapies against Intractable Diseases, Institute for Comprehensive Medical Science (ICMS), Fujita Health University, Toyoake, Japan.
  • Department of Medical Technology, School of Health Sciences, Gifu University of Medical Science, Seki, Japan.

References

  1. 1.0 1.1 1.2 Keisuke Hitachi, Masashi Nakatani, Akihiko Takasaki,Yuya Ouchi, Akiyoshi,Uezumi1, Hiroshi Ageta1, Hidehito Inagaki,Hiroki Kurahashi & Kunihiro Tsuchida1. Myogenin promoter‐associated lncRNA Myoparr is essential for myogenic differentiation.EMBO reports,2019 Mar;20(3).

Sequence